<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03417388</url>
  </required_header>
  <id_info>
    <org_study_id>IRB201701142 -A</org_study_id>
    <secondary_id>W81XWH-17-2-0030</secondary_id>
    <secondary_id>OCR17268</secondary_id>
    <secondary_id>IRB201802734</secondary_id>
    <nct_id>NCT03417388</nct_id>
  </id_info>
  <brief_title>Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD</brief_title>
  <acronym>WARRIOR</acronym>
  <official_title>Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Ischemia-IMT (Ischemia-Intensive Medical Treatment Reduces Events in Women with
      Non-Obstructive CAD), subtitle: Women's Ischemia Trial to Reduce Events in Non-Obstructive
      CAD (WARRIOR) trial is a multicenter, prospective, randomized, blinded outcome evaluation
      (PROBE design) evaluating intensive statin/ACE-I (or ARB)/aspirin treatment (IMT) vs. usual
      care (UC) in 4,422 symptomatic women patients with symptoms and/or signs of ischemia but no
      obstructive CAD. The hypothesis is that IMT will reduce major adverse coronary events (MACE)
      20% vs. UC. The primary outcome is first occurrence of MACE as death, nonfatal MI, nonfatal
      stroke/transient ischemic attack (TIA) or hospitalization for heart failure or angina.
      Secondary outcomes include quality of life, time to &quot;return to duty&quot;/work, health resource
      consumption, angina, cardiovascular (CV) death and primary outcome components. Events will be
      adjudicated by an experienced Clinical Events Committee (CEC). Follow-up will be 3-years
      using 50 sites: primarily VA and Active Duty Military Hospitals/Clinics and a National
      Patient-Centered Clinical Research Network (PCORnet) clinical data research network
      (CDRN)(OneFlorida Consortium).

      This study is being conducted to determine whether intensive medication treatment to modify
      risk factors and vascular function in women patients with coronary arteries showing no flow
      limit obstruction but with cardiac symptoms (i.e., chest pain, shortness of breath) will
      reduce the patient's likelihood of dying, having a heart attack, stroke/TIA or being
      hospitalized for cardiac reasons. The results will provide evidence data necessary to inform
      future guidelines regarding how best to treat this growing population of patients, and
      ultimately improve the patient's cardiac health and quality of life and reduce health-care
      costs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      WARRIOR trial is a multi-site, PROBE design, that will evaluate an intensive statin/ACE-I (or
      ARB)/aspirin treatment strategy (IMT) vs. primary prevention risk factor therapy treatment
      strategy (UC) in 4,422 symptomatic (chronic angina or equivalent) women with non-obstructive
      CAD (&lt;50% diameter narrowing).

      There will be ~50 US sites, including VA/ military and OneFlorida CDRN sites, with a proven
      record in prior trials. The investigators will use web-based, real-time data entry, and
      management University of Florida Data Management System (UFDMS) for site selection,
      screening, participant eligibility confirmation, enrollment, and randomization. Participants
      will be recruited from screened women with symptoms suspected to be ischemic with
      non-obstructive CAD by invasive coronary angiogram or CT angiogram. The high dose statin
      (atorvastatin or rosuvastatin) and ACE-I (lisinopril) [or ARB (losartan)] are generic
      commonly used medications previously demonstrated effective for improving angina, stress
      testing, myocardial perfusion and coronary microvascular flow reserve in small size trials in
      this population. Additionally, aspirin will also be recommended to IMT participants without
      contraindications or excess bleeding risk, however aspirin will not be provided by the study.
      Both the groups will also receive Lifestyle Counseling (PACE Assessment), and the same visit
      schedule and &quot;face-time&quot; with site staff to reduce bias. Events will be adjudicated by the
      Clinical Events Committee (CEC), according to objective criteria and masked to treatment
      assignment clues.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a PROBE design, that will evaluate an intensive statin/ACE-I (or ARB) treatment strategy (IMT) vs. primary prevention risk factor therapy treatment strategy (UC) in symptomatic (chronic angina or equivalent) women with non-obstructive CAD.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The Clinical Events Committee (CEC) will be masked to all treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>All Cause Death incidents reported between the two groups</measure>
    <time_frame>3 years</time_frame>
    <description>Collection of all deaths reported between the two groups will use the log rank test for comparison of outcomes. Although the power analysis required the exponential assumption, the actual statistical test is free of assumptions, as the null hypothesis is that the survival distributions for the two strategies are the same, and therefore the null hazard ratio is 1.00 (proportional hazards).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-fatal myocardial infarction (MI) incidents reported between the two groups</measure>
    <time_frame>3 years</time_frame>
    <description>Collection of all non-fatal MI's reported between the two groups will use the log rank test for comparison of outcomes. Although the power analysis required the exponential assumption, the actual statistical test is free of assumptions, as the null hypothesis is that the survival distributions for the two strategies are the same, and therefore the null hazard ratio is 1.00 (proportional hazards). MI definition follows universal criteria for Types 1-5 MI events. Specifically, the use of the &quot;Third Universal Definition of Myocardial Infarction&quot; detection of a rise and/or fall of cardiac biomarker values, with at least one value &gt;99th percentile upper reference limit and preferred biomarker is Cardiac troponin (cTn).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke/TIA incidents reported between the two groups</measure>
    <time_frame>3 years</time_frame>
    <description>Collection of all strokes or transient ischemic attack (TIA) reported between the two groups will use the log rank test for comparison of outcomes. Although the power analysis required the exponential assumption, the actual statistical test is free of assumptions, as the null hypothesis is that the survival distributions for the two strategies are the same, and therefore the null hazard ratio is 1.00 (proportional hazards). The stroke definition is new onset neurological defect of central origin confirmed by brain imaging (CT or MRI) evidence of cerebral infarction or intracerebral hemorrhage. The definition of TIA is the same as stroke except no confirmation by brain imaging, but confirmed by a neurologist consult.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalizations for cardiovascular events reported between the two groups</measure>
    <time_frame>3 years</time_frame>
    <description>Collection of all hospitalization for cardiovascular events reported between the two groups will use the log rank test for comparison of outcomes. Although the power analysis required the exponential assumption, the actual statistical test is free of assumptions, as the null hypothesis is that the survival distributions for the two strategies are the same, and therefore the null hazard ratio is 1.00 (proportional hazards). Cardiovascular causes includes accelerated angina, persistent angina, unstable angina.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalizations for heart failure incidents reported between the two groups</measure>
    <time_frame>3 years</time_frame>
    <description>Collection of all hospitalizations for heart failure between the two groups will use the log rank test for comparison of outcomes. Although the power analysis required the exponential assumption, the actual statistical test is free of assumptions, as the null hypothesis is that the survival distributions for the two strategies are the same, and therefore the null hazard ratio is 1.00 (proportional hazards).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4422</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Intensive Medical Treatment (IMT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The IMT-assigned women will receive high dose potent statin, and moderate dose of an ACE-I (lisinopril) or ARB (losartan). Aspirin will also be recommended to IMT women without contraindications or bleeding risk. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and &quot;face-time&quot; with site staff to reduce bias.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care (UC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The UC-assigned women will maintain standard of care. This group will also receive Lifestyle Counseling (PACE Assessment), Quality of Life questionnaires, and the same visit schedule and &quot;face-time&quot; with site staff to reduce bias.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose potent statin</intervention_name>
    <description>The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.</description>
    <arm_group_label>Intensive Medical Treatment (IMT)</arm_group_label>
    <other_name>atorvastatin or rosuvastatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACE-I (lisinopril) or ARB (losartan)</intervention_name>
    <description>Angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) are widely prescribed for primary hypertension.</description>
    <arm_group_label>Intensive Medical Treatment (IMT)</arm_group_label>
    <other_name>ACE-I or ARB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Will be recommended to IMT women without contraindications or bleeding risk.</description>
    <arm_group_label>Intensive Medical Treatment (IMT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lifestyle Counseling</intervention_name>
    <description>The PACE Lifestyle Assessment Intervention which is a program to assist with smoking cessation, weight loss, and exercise.</description>
    <arm_group_label>Intensive Medical Treatment (IMT)</arm_group_label>
    <other_name>PACE Lifestyle Intervention</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality of Life Questionnaires</intervention_name>
    <description>Quality of Life Questionnaires will be obtained.</description>
    <arm_group_label>Intensive Medical Treatment (IMT)</arm_group_label>
    <arm_group_label>Usual Care (UC)</arm_group_label>
    <other_name>QOL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signs and symptoms of suspected ischemia prompting referral for further evaluation by
             cardiac catheterization or coronary angiogram or coronary CT angiogram within 5 years
             from consent

          -  Willing to provide written informed consent

          -  Non-obstructive CAD defined as 0 to 49% diameter reduction of a major epicardial
             vessel or a FFR&gt;0.80

        Exclusion Criteria:

          -  History of noncompliance (with medical therapy, protocol, or follow-up)

          -  History of non-ischemic dilated or hypertrophic cardiomyopathy

          -  Documented acute coronary syndrome(ACS) within previous 30 days

          -  Left ventricular ejection fraction (LVEF) &lt;40%, New York Heart Association heart
             failure (NYHA HF) class III-IV, or hospitalization for Reduced ejection fraction
             (HFrEF) within 180 days

          -  Stroke within previous 180 days or intracranial hemorrhage at any time

          -  End-stage renal disease, on dialysis, or estimated glomerular filtration rate (eGFR)
             &lt;30 ml/min.

          -  Severe valvular disease or likely to require surgery/Transcatheter aortic valve
             replacement (TVAR) within 3 years

          -  Life expectancy &lt;3-yrs. due to non-cardiovascular comorbidity

          -  Enrolled in a competing clinical trial

          -  Prior intolerance to both an ACE-I and ARB

          -  If intolerant to a statin unless taking a PCSK9 as a statin replacement by their
             clinical provider

          -  Pregnancy (all pre-menopausal females must have negative urine pregnancy test if
             randomized to IMT before study drugs are prescribed. If they have not gone through
             menopause, had a hysterectomy, oophorectomy, or sterilization such as tubal ligation
             procedure)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carl J Pepine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana D Leach, ARNP-BC</last_name>
    <phone>352-273-8933</phone>
    <email>dana.leach@medicine.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debra Landers</last_name>
    <phone>352-273-7901</phone>
    <email>debra.landers@medicine.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiology Associates of Mobile, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruth Wagner</last_name>
      <phone>251-340-6870</phone>
    </contact>
    <investigator>
      <last_name>Jason Cole, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alabama Heart and Vascular Medicine</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kimberly Skelding, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Heart Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norma Moy</last_name>
      <phone>310-423-7609</phone>
      <email>NormaPriscilla.Moy@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Chrisandra Shufelt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthew Budoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clearwater Cardiovascular Consultants Clinical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>A-Hamid Hakki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Palm Cardiovascular Research Institute</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gustavo Cardenas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Family Medicine at Eastside Community Practice</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Family Medicine at Hampton Oaks Medical Plaza (Adults and Peds)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Internal Medicine at Tower Hill</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Family Medicine at Haile Plantation (Adults &amp; Peds)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Malcom Randall VA Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Stinson, BSN</last_name>
      <phone>352-548-7422</phone>
    </contact>
    <investigator>
      <last_name>Carsten Schmalfuss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Clinic at UF Health UF</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Internal Medicine at UF Health Medical Plaza</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UF Health at the University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiology West at Doctors Park</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Family Medicine at 4th Ave</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Family Medicine at Old Town (Adults and Peds)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32680</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baptist Health</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ruple Galani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Naval Hospital Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Volk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UF Primary Care at Lake City SW</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UF Primary Care at Lake City West</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Daytona Heart Group</name>
      <address>
        <city>Multiple Locations</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Glenn Rayos, MD</last_name>
      <phone>386-258-8722</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwest Florida Research Institute</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Halbert, Pharm.D.</last_name>
      <phone>239-213-0213</phone>
      <phone_ext>201</phone_ext>
    </contact>
    <investigator>
      <last_name>Ariel De La Rosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Instititute of Central Florida</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hima Mikkilineni, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ocala Research Institute Inc.</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34480</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesh Prashad, MD</last_name>
      <phone>352-412-5989</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arnold Einhorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naval Hospital Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32512</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carrie Gray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Center of Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mahfouz Shahawy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Tampa - Pepin Heart Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles R Lambert, MD</last_name>
      <phone>813-615-7527</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Interventional Cardiac Consultants</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos J Bayron, MD</last_name>
      <phone>727-842-9526</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>BayCare Medical Group</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pam Paul</last_name>
    </contact>
    <investigator>
      <last_name>Lang Lin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Caroline Ball</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiovascular Research and Education Foundation</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vijay Mehta, MD</last_name>
      <phone>574-522-0337</phone>
    </contact>
    <investigator>
      <last_name>Vijay Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Heart and Vascular Specialists</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Fulks</last_name>
      <phone>913-253-3022</phone>
      <email>Elizabeth.Fulks@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Bloom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gretchen Wells, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Weber, MD</last_name>
      <phone>301-400-2383</phone>
      <email>lauren.a.weber3.mil@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Lauren Weber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essentia Institute of Rural Health</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn Rikkola</last_name>
      <phone>218-786-2077</phone>
      <email>Kaitlyn.Rikkola@EssentiaHealth.org</email>
    </contact>
    <investigator>
      <last_name>Catherine Benziger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Retu Saxena, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cardiology Associates Research. LLC</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>William Calhoun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Health Research Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mel Romsa</last_name>
      <phone>402-343-8535</phone>
    </contact>
    <investigator>
      <last_name>Arun Kanmantha-Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Silver State Cardiology</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leonard Parilak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bassett Healthcare Network</name>
      <address>
        <city>Cooperstown</city>
        <state>New York</state>
        <zip>13326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dhananjai Menzies</last_name>
    </contact>
    <investigator>
      <last_name>Dhananjai Menzies</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jamaica Hospital Medical Center</name>
      <address>
        <city>Richmond Hill</city>
        <state>New York</state>
        <zip>11418</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aditya Mangla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peak Clinical Trials, LLC</name>
      <address>
        <city>Apex</city>
        <state>North Carolina</state>
        <zip>27502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Barbara White</last_name>
      <phone>919-267-6209</phone>
    </contact>
    <investigator>
      <last_name>Mehar Ambati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart House Research Foundation</name>
      <address>
        <city>Springfield</city>
        <state>Ohio</state>
        <zip>45505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sayed T Rizvi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seton Heart Institute</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Benedict</last_name>
      <phone>512-803-1761</phone>
    </contact>
    <investigator>
      <last_name>Caitlin Giesler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>Fort Sam Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christopher Pickett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanda Fikes</last_name>
      <phone>254-724-5373</phone>
    </contact>
    <investigator>
      <last_name>Robert Widmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Taylor</last_name>
      <phone>434-982-1058</phone>
    </contact>
    <investigator>
      <last_name>Angela Taylor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chippenham Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Burton</last_name>
      <email>Stephanie.Burton@HCAhealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Denise Dietz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Morgan</last_name>
      <phone>304-285-1947</phone>
    </contact>
    <investigator>
      <last_name>Irfan Zeb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Caribbean Healthcare System</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiomarie Ojeda-Rodriguez</last_name>
      <phone>787-641-7582</phone>
      <phone_ext>10515</phone_ext>
    </contact>
    <investigator>
      <last_name>Sonia Vicenty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 24, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Angiography</keyword>
  <keyword>Coronary CT Angiogram</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Non-obstructive CAD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

